Xvivo Perfusion Aktiebolag financials
Xvivo Perfusion Aktiebolag
549300G2464FYLS14B41 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 597.5M | SEK 415.3M |
| Cost of sales | SEK 152.4M | SEK 118.3M |
| Gross profit | SEK 445.1M | SEK 297.0M |
| Other income | SEK 9.3M | SEK 4.7M |
| Administrative expenses | SEK 76.9M | SEK 71.0M |
| Operating profit (EBIT) | SEK 4.2M | SEK 6.4M |
| Net finance income / (cost) | SEK 90.3M | SEK 15.9M |
| Finance costs | SEK 46.3M | SEK 55.7M |
| Profit before tax | SEK 94.5M | SEK 22.3M |
| Income tax expense | SEK 2.7M | SEK 3.9M |
| Profit for the year | SEK 91.8M | SEK 18.4M |
| — attributable to owners | SEK 91.8M | SEK 18.4M |
| Total comprehensive income | SEK 64.9M | SEK 84.1M |
| Per share | ||
| Basic EPS | SEK 3.07 | SEK 0.62 |
| Diluted EPS | SEK 3.07 | SEK 0.62 |
| Free cash flow / share | SEK 0.11 | SEK 0.33 |
| Cash flow statement | ||
| Net cash from operating activities | SEK 46.3M | SEK 27.9M |
| Income taxes paid | SEK 7.0M | -SEK 199.0K |
| Net cash from investing activities | -SEK 161.6M | -SEK 197.6M |
| Purchase of PP&E (capex) | SEK 43.0M | SEK 18.2M |
| Purchase of intangibles | SEK 100.9M | SEK 112.8M |
| Net cash from financing activities | SEK 418.5M | -SEK 6.8M |
| Lease liability payments | SEK 10.7M | SEK 7.3M |
| Net change in cash | SEK 303.2M | -SEK 176.6M |
| Balance sheet | ||
| Total assets | SEK 2.20B | SEK 1.73B |
| Non-current assets | SEK 1.37B | SEK 1.27B |
| Property, plant & equipment | SEK 97.6M | SEK 47.6M |
| Intangible assets & goodwill | SEK 591.4M | SEK 625.3M |
| Current assets | SEK 826.4M | SEK 467.5M |
| Inventories | SEK 141.6M | SEK 106.6M |
| Trade & other receivables | SEK 98.1M | SEK 94.5M |
| Cash & equivalents | SEK 546.1M | SEK 246.5M |
| Total equity | SEK 1.95B | SEK 1.43B |
| Non-current liabilities | SEK 116.1M | SEK 168.1M |
| Long-term borrowings | SEK 21.2M | SEK 4.5M |
| Current liabilities | SEK 134.5M | SEK 134.9M |
| Short-term borrowings | SEK 10.3M | SEK 5.5M |
| Deferred tax liabilities | SEK 29.3M | SEK 25.8M |
| Derived metrics | ||
| Free cash flow | SEK 3.3M | SEK 9.7M |
| Operating margin | 0.7% | 1.5% |
| Net margin | 15.4% | 4.4% |
| Return on equity | 4.7% | 1.3% |
| Cash conversion ratio | 0.50× | 1.51× |
| Capex coverage | 1.08× | 1.53× |
| Other reported items | ||
| Additional Paidin Capital | SEK 1.76B | SEK 1.31B |
| Adjusted Weighted Average Shares | 29.9M | 29.5M |
| Adjustments For Decrease Increase In Inventories | -SEK 33.5M | -SEK 6.3M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 25.0M | -SEK 26.9M |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 19.3M | SEK 11.0M |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | -SEK 2.0M | SEK 27.5M |
| Cash Flows From Used In Operations Before Changes In Working Capital | SEK 85.5M | SEK 50.0M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | SEK 17.7M | SEK 67.4M |
| Comprehensive Income Attributable To Owners of Parent | SEK 64.9M | SEK 84.1M |
| Computer Software | SEK 1.7M | SEK 2.3M |
| Copyrights Patents and Other Industrial Property Rights Service and Operating Rights | SEK 5.9M | SEK 6.2M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 72.6M | SEK 55.8M |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 20.3M | SEK 10.1M |
| Current Tax Assets Current | SEK 7.2M | SEK 4.4M |
| Current Tax Liabilities Current | SEK 11.9M | SEK 1.3M |
| Deferred Tax Assets | SEK 50.7M | SEK 39.3M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -SEK 3.7M | SEK 24.5M |
| Equity and Liabilities | SEK 2.20B | SEK 1.73B |
| Finance Income | SEK 136.6M | SEK 71.6M |
| Increase Decrease Through Transactions With Owners | SEK 450.0M | SEK 60.6M |
| Issue of Equity | SEK 447.6M | SEK 59.8M |
| Issued Capital | SEK 805.0K | SEK 762.0K |
| Liabilities | SEK 250.6M | SEK 302.9M |
| Other Comprehensive Income | -SEK 26.9M | SEK 65.7M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -SEK 26.9M | SEK 65.7M |
| Other Current Liabilities | SEK 3.7M | SEK 33.8M |
| Other Current Receivables | SEK 13.0M | SEK 5.3M |
| Other Expense By Function | SEK 5.1M | SEK 2.5M |
| Other Longterm Provisions | SEK 1.2M | SEK 701.0K |
| Other Noncurrent Financial Assets | SEK 582.0K | SEK 411.0K |
| Other Noncurrent Liabilities | SEK 64.4M | SEK 137.1M |
| Other Reserves | SEK 60.9M | SEK 87.8M |
| Proceeds From Issuing Shares | SEK 429.3M | -SEK 368.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | SEK 174.0K | SEK 0 |
| Research and Development Expense | SEK 135.9M | SEK 69.3M |
| Retained Earnings | SEK 119.6M | SEK 27.8M |
| Selling Expense | SEK 232.3M | SEK 152.4M |
| Share Issue Related Cost | SEK 10.8M | SEK 368.0K |
| Trade and Other Current Payables To Trade Suppliers | SEK 36.1M | SEK 38.5M |
| Weighted Average Shares | 29.9M | 29.5M |
Every line item above is a fact tagged in Xvivo Perfusion Aktiebolag's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.